With new PhIII data in hand, Dermavant lines up topical psoriasis contender for a sprint to the finish line
In the next couple months, Dermavant CEO Todd Zavodnick says he’ll sprint to the FDA with tapinarof, the company’s “cosmetically elegant” vanishing cream to treat psoriasis. But before that, he has more Phase III data to share.
Around 20% of moderate to severe plaque psoriasis patients given tapinarof in two Phase III trials achieved 90% disease clearance, measured by the Psoriasis Area and Severity Index (PASI 90) at Week 12, Zavodnick shared Friday at the American Academy of Dermatology virtual meeting. And around 67% and 60% of patients in the trials felt itch relief starting as early as Week 2.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.